|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
La Vecchia C, Malvezzi M, Bosetti C,
Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer
mortality and incidence: A global overview. Int J Cancer.
136:2187–2195. 2015. View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang L, Zheng RS, Wang N, Zeng HM, Yuan
YN, Zhang SW, Li HC, Liu S, Chen WQ and He J: Analysis of incidence
and mortality of thyroid cancer in China, 2013. Zhonghua Zhong Liu
Za Zhi. 39:862–867. 2017.In Chinese. PubMed/NCBI
|
|
5
|
Baloch ZW and LiVolsi VA: Special types of
thyroid carcinoma. Histopathology. 72:40–52. 2018. View Article : Google Scholar
|
|
6
|
Azar FK, Lee SL and Rosen JE: Medullary
thyroid cancer: An update for surgeons. Am Surg. 81:1–8. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Massimino M, Evans DB, Podda M, Spinelli
C, Collini P, Pizzi N and Bleyer A: Thyroid cancer in adolescents
and young adults. Pediatr Blood Cancer. 65:e270252018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raue F and Frank-Raue K: Thyroid cancer:
Risk-stratified management and individualized therapy. Clin Cancer
Res. 22:5012–5021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu S, Liu X, Li J, Zhou H, Carr MJ, Zhang
Z and Shi W: Long noncoding RNAs: Novel regulators of virus-host
interactions. Rev Med Virol. 29:e20462019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liz J and Esteller M: lncRNAs and
microRNAs with a role in cancer development. Biochim Biophys Acta.
1859:169–176. 2016. View Article : Google Scholar
|
|
11
|
Sui F, Ji M and Hou P: Long non-coding
RNAs in thyroid cancer: Biological functions and clinical
significance. Mol Cell Endocrinol. 469:11–22. 2018. View Article : Google Scholar
|
|
12
|
Gugnoni M and Ciarrocchi A: Long noncoding
RNA and epithelial mesenchymal transition in cancer. Int J Mol Sci.
20:19242019. View Article : Google Scholar :
|
|
13
|
Lee KT, Gopalan V and Lam AK: Roles of
long-non-coding RNAs in cancer therapy through the PI3K/Akt
signalling pathway. Histol Histopathol. 34:593–609. 2019.PubMed/NCBI
|
|
14
|
Fu D, Zhang Y and Cui H: Long noncoding
RNA CCAT2 is activated by E2F1 and exerts oncogenic properties by
interacting with PTTG1 in pituitary adenomas. Am J Cancer Res.
8:245–255. 2018.PubMed/NCBI
|
|
15
|
Ruan R and Zhao XL: LncRNA CCAT2 enhances
cell proliferation via GSK3β/β-catenin signaling pathway in human
osteosarcoma. Eur Rev Med Pharmacol Sci. 22:2978–2984.
2018.PubMed/NCBI
|
|
16
|
Fosselteder J, Calin GA and Pichler M:
Long non-coding RNA CCAT2 as a therapeutic target in colorectal
cancer. Expert Opin Ther Targets. 22:973–976. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miao S, Jing M, Sheng R, Cui D, Lu S,
Zhang X, Jing S, Zhang X, Shan T, Shan H, et al: The analysis of
differential diagnosis of benign and malignant thyroid nodules
based on ultrasound reports. Gland surgery. 9:653–660. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee H, Lee M, Byun SS, Lee SE and Hong SK:
Evaluation of prostate cancer stage groups updated in the 8th
edition of the American Joint Committee on cancer
tumor-node-metastasis staging manual. Clin Genitourin Cancer.
17:e221–e226. 2019. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Srivastava NS and Srivastava RAK: Curcumin
and quercetin synergistically inhibit cancer cell proliferation in
multiple cancer cells and modulate Wnt/β-catenin signaling and
apoptotic path-ways in A375 cells. Phytomedicine. 52:117–128. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao C, Qiao C, Zong L and Chen Y: Long
non-coding RNA-CCAT2 promotes the occurrence of non-small cell lung
cancer by regulating the Wnt/β-catenin signaling pathway. Oncol
Lett. 16:4600–4606. 2018.PubMed/NCBI
|
|
22
|
Ma Y, Hu X, Shang C, Zhong M and Guo Y:
Silencing of long non-coding RNA CCAT2 depressed malignancy of oral
squamous cell carcinoma via Wnt/β-catenin pathway. Tumour Biol.
39:10104283177176702017. View Article : Google Scholar
|
|
23
|
Murugan AK, Munirajan AK and Alzahrani AS:
Long noncoding RNAs: Emerging players in thyroid cancer
pathogenesis. Endocr Relat Cancer. 25:R59–R82. 2018. View Article : Google Scholar
|
|
24
|
Zhang R, Hardin H, Chen J, Guo Z and Lloyd
RV: Non-coding RNAs in thyroid cancer. Endocr Pathol. 27:12–20.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xin Y, Li Z, Zheng H, Chan MTV and Ka Kei
Wu W: CCAT2: A novel oncogenic long non-coding RNA in human
cancers. Cell Prolif. 50:e123422017. View Article : Google Scholar
|
|
26
|
Ling H, Spizzo R, Atlasi Y, Nicoloso M,
Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, et al:
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic
progression and chromosomal instability in colon cancer. Genome
Res. 23:1446–1461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jo S, Ha TK, Han SH, Kim ME, Jung I, Lee
HW, Bae SK and Lee JS: Myricetin induces apoptosis of human
anaplastic thyroid cancer cells via mitochondria dysfunction.
Anticancer Res. 37:1705–1710. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tirapelli DPDC, Lustosa IL, Menezes SB,
Franco IM, Rodrigues AR, Peria FM, Marinho AMDN, Serafini LN,
Carlotti CG Jr and Tirapelli LF: High expression of XIAP and Bcl-2
may inhibit programmed cell death in glioblastomas. Arq
Neuropsiquiatr. 75:875–880. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Warren CFA, Wong-Brown MW and Bowden NA:
BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis.
10:1772019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hamivand Z, Haddadi G and Fardid R:
Expression of Bax and Bcl2 genes in peripheral blood lymphocytes of
patients with differentiated thyroid cancer. J Med Phys. 43:41–45.
2018.PubMed/NCBI
|
|
31
|
Albasri AM, Elkablawy MA, Ansari IA and
Alhujaily AS: Prognostic significance of cyclin D1 Over-expression
in colorectal cancer: An experience from Madinah, Saudi Arabia.
Asian Pac J Cancer Prev. 20:2471–2476. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nusse R and Clevers H: Wnt/β-catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shang S, Hua F and Hu ZW: The regulation
of β-catenin activity and function in cancer: Therapeutic
opportunities. Oncotarget. 8:33972–33989. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/beta-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar
|
|
35
|
Bi W, Huang J, Nie C, Liu B, He G, Han J,
Pang R, Ding Z, Xu J and Zhang J: CircRNA circRNA_102171 promotes
papillary thyroid cancer progression through modulating
CTNNBIP1-dependent activation of β-catenin pathway. J Exp Clin
Cancer Res. 37:2752018. View Article : Google Scholar
|
|
36
|
Jing N, Huang T, Guo H, Yang J, Li M, Chen
Z and Zhang Y: LncRNA CASC15 promotes colon cancer cell
proliferation and metastasis by regulating the
miR4310/LGR5/Wnt/β-catenin signaling pathway. Mol Med Rep.
18:2269–2276. 2018.PubMed/NCBI
|
|
37
|
Zarkou V, Galaras A, Giakountis A and
Hatzis P: Crosstalk mechanisms between the WNT signaling pathway
and long non-coding RNAs. Noncoding RNA Res. 3:42–53. 2018.
View Article : Google Scholar : PubMed/NCBI
|
